# US 2026/0083777 A1 · Citrullinated antigen-specific chimeric antigen receptors for targeting regulatory t cells to treat hidradenitis suppurativa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083777 A1
- Document ID: US20260083777A1
- Status: Published application
- Kind: A1
- Application number: 19/112,106
- Filed: 2023-09-18
- Published: 2026-03-26
- Earliest claimed: 2022-09-19
- Assignees: Sonoma Biotherapeutics, Inc.
- Applicants: Sonoma Biotherapeutics, Inc.
- Inventors: Leonard DRAGONE; Joshua BEILKE
- Web page: https://patentgrep.com/patent/US20260083777A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 17/00: Drugs for dermatological disorders
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 16/18: against material from animals or humans
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- A61K 2239/13: Antibody-based
- A61K 2239/17: Hinge-spacer domain
- A61K 2239/21: Transmembrane domain
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subjects with hidradenitis suppurativa. Further disclosed are T cells, and in particular, Treg cells that express these CARs. Administration of these CAR-T cells is useful in the treatment of hidradenitis suppurativa.

## Claims

### Claim 1

A method of treating a subject suffering from hidradenitis suppurativa, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a plurality of modified regulatory T (Treg) cells and a pharmaceutically acceptable excipient, wherein
the modified Treg cells express a chimeric antigen receptor (CAR) comprising an antigen-binding domain, a hinge domain, a transmembrane domain, one or more co-stimulatory domains, and an intracellular signaling domain,
the antigen binding domain specifically binds to one or more different citrullinated proteins or citrullinated fragments thereof, and
the modified Treg cells are CD4+, CD25+ and CD127lo.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antigen-binding domain of the CAR specifically binds to citrullinated vimentin.

### Claim 3 (depends on 1)

The method of claim 1, wherein the antigen-binding domain of the CAR binds to all three of (i) citrullinated vimentin, (ii) citrullinated filaggrin, and (iii) citrullinated fibrinogen, or citrullinated peptides fragments thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the antigen-binding domain of the CAR comprises a VH domain and a VL domain, wherein:
(i) the VH domain comprises a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:32, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:34, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:36, and
(ii) the VL domain of the target-binding domain comprises a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:39, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:43.

### Claim 5 (depends on 3)

The method of claim 3, wherein the antigen-binding domain of the CAR comprises a VH domain and a VL domain, wherein:
(i) the VH domain comprises a VH-CDR1 comprising the amino acid sequence of SEQ ID NO:53, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO:55, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO:57, and
(ii) the VL domain of the target-binding domain comprises a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:60, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:62, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:64.

### Claim 6 (depends on 1)

The method of claim 1, wherein the intracellular signaling domain of the CAR is derived from CD3-zeta.

### Claim 7 (depends on 1)

The method of claim 1, wherein the at least one co-stimulatory domain of the CAR comprises a co-stimulatory domain of a member of the group consisting of FceR1 g, Fcg, CD28, CD134 (OX40), CD137 (4-1BB), CTLA-4, CTLA-4/CD-28 hybrid, DAP10, CD27, 2B4, and combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the antigen-binding domain of the CAR comprises an antibody, an antibody fragment, a camelid nanobody, a heavy chain only antibody or an aptamer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the transmembrane domain of the CAR is a CD8 transmembrane domain or a CD28 transmembrane domain.

### Claim 10 (depends on 1)

The method of claim 1, wherein the hinge domain of the CAR is a CD8 hinge domain or a CD28 hinge domain.

### Claim 11 (depends on 1)

The method of claim 1, wherein the CAR further comprising a signal peptide.

### Claim 12 (depends on 11)

The method of claim 11, wherein the signal peptide of the CAR is a CD8 signal peptide or a GM-CSF signal peptide.

### Claim 13 (depends on 1)

The method of claim 1, wherein the antigen-binding domain of the CAR comprises a single chain fragment.

### Claim 14 (depends on 13)

The method of claim 13, wherein the single chain fragment comprises a single chain variable fragment (scFv).

### Claim 15 (depends on 14)

The method of claim 14, wherein the scFv fragment comprises:
(a) a VH domain comprising the amino acid sequence of SEQ ID NO:1 or the amino acid sequence having at least 95% sequence identity to SEQ ID NO:1; and
(b) a VL domain comprising the amino acid sequence of SEQ ID NO:4 or the amino acid sequence having at least 95% sequence identity to SEQ ID NO:4.

### Claim 16 (depends on 14)

The method of claim 14, wherein the scFv fragment comprises:
(a) a VH domain comprising the amino acid sequence of SEQ ID NO:49 or the amino acid sequence having at least 95% sequence identity to SEQ ID NO:49; and
(b) a VL domain comprising the amino acid sequence of SEQ ID NO:50 or the amino acid sequence having at least 95% sequence identity to SEQ ID NO:50.

### Claim 17 (depends on 14)

The method of claim 14, wherein the scFv fragment comprises:
(a) a VH selected from:
(1) SBT01 VH (M)
(SEQ ID NO: 1)
HLHLQESGPGLVKPSETLSLTCTVSGGSINDTTYYWGWIRQPPGKGLEW
IGSIYYRGNTHYNSSLRSRVTMSVDTSKNRFSLKVTSVTAADTAVYYCA
RLDPFDYWGRGTLVTVSS;
or
(2) SBT01 VH (G)
(SEQ ID NO: 2)
QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEW
IGSIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCA
RLDPFDYWGRGTLVTVSS;
and
(b) a VL selected from:
(1) SBT01 VL (M)
(SEQ ID NO: 3)
SYVLTQPPSVSLAPGETATITCGGDDIENQNVNWYQQKSGQAPMLLIFF
DTRRPSGIPERFSGSRSEDTANLTITRVEAGDDADYFCQVYDRKTDHQV
FGPGTTVTVL
or
(2) SBT01 VL (G)
(SEQ ID NO: 4)
SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYY
DSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHQV
FGTGTKVTVL.

### Claim 18 (depends on 17)

The method of claim 17, wherein the VH-VL fragments are joined by a linker selected from the group consisting of (i) GGGSx3 (SEQ ID NO:20), (ii) Whitlow 218 (SEQ ID NO:21), and (iii) AB Pur (SEQ ID NO:22).

### Claim 19 (depends on 18)

The method of claim 18, wherein the scFv comprises the amino acid sequence of:
(a) SBT01 G-VHVL-GGGSx3 Linker of SEQ ID NO:5; or
(b) SBT01 G-VHVL-Whitlow 218 Linker of SEQ ID NO:6; or
(c) SBT01 G-VHVL-AB pur Linker of SEQ ID NO:7; or
(d) U01-VHVL-AB pur Linker of SEQ ID NO:51.

### Claim 20 (depends on 1)

The method of claim 1, wherein the modified Treg cells are human T cells and the subject is a human patient.

### Claim 21 (depends on 20)

The method of claim 20, wherein the modified Treg cells are a primary T cells.

### Claim 22 (depends on 21)

The method of claim 21, wherein the pharmaceutical composition is administered intravenously.

### Claim 23

A method of treating a subject suffering from hidradenitis suppurativa, the method comprising:
(a) isolating T cells from a biological sample obtained from the subject;
(b) enriching the T cells for T regulatory cells (Treg);
(c) transfecting the enriched Treg cells with an expression vector encoding a chimeric antigen receptor (CAR) comprising an antigen-binding domain, a hinge domain, a transmembrane domain, one or more co-stimulatory domains, and an intracellular signaling domain to produce modified Treg cells expressing the CAR, wherein
the antigen binding domain specifically binds to one or more different citrullinated proteins or citrullinated fragments thereof, and
the modified Treg cells are CD4+, CD25+ and CD127lo;
(d) expanding the modified Treg cells; and
(e) administering the modified Treg cells to the subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein the expansion comprises using anti-CD3/CD28 coated beads.

### Claim 25 (depends on 23)

The method of claim 23, wherein the expansion does not comprise using anti-CD3/CD28 coasted beads.

### Claim 26 (depends on 23)

The method of claim 23, wherein the transfection occurs by use of a viral vector, electroporation, heat shock, bacteriophage, sonication, or calcium phosphate.

### Claim 27 (depends on 23)

The method of claim 23, further comprising administering one or more anti-inflammatory and/or therapeutic agents to the subject.

### Claim 28 (depends on 27)

The method of claim 27, wherein the one or more anti-inflammatory agents comprises an antibody that inhibits a pro-inflammatory cytokine.

### Claim 29 (depends on 28)

The method of claim 28, wherein the anti-inflammatory agents comprise an anti-TNF antibody, an anti-IL-6 antibody, or a combination thereof.

### Claim 30 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 23-29 and further comprising limitations of any one of claims 2-22.

### Claim 31

Use of a plurality of modified regulatory T (Treg) cells in the manufacture of a medicament for treating hidradenitis suppurativa in a subject, wherein
the modified Treg cells express a chimeric antigen receptor (CAR) comprising an antigen-binding domain, a hinge domain, a transmembrane domain, one or more co-stimulatory domains, and an intracellular signaling domain,
the antigen binding domain specifically binds to one or more different citrullinated proteins or citrullinated fragments thereof, and
the modified Treg cells are CD4+, CD25+ and CD127lo.

### Claim 32 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The use of embodiment 31 and further comprising limitations of any one of claims 2-22.

### Claim 33

A plurality of modified regulatory T (Treg) cells for use in a method of treating hidradenitis suppurativa in a subject, the method comprising administering to the subject the plurality of modified regulatory T (Treg) cells, wherein
the modified Treg cells express a chimeric antigen receptor (CAR) comprising an antigen-binding domain, a hinge domain, a transmembrane domain, one or more co-stimulatory domains, and an intracellular signaling domain,
the antigen binding domain specifically binds to one or more different citrullinated proteins or citrullinated fragments thereof, and
the modified Treg cells are CD4+, CD25+ and CD127lo.

### Claim 34 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The plurality of modified Treg cells for use of embodiment 33 and further comprising limitations of any one of claims 2-22.
